Medicinal Chemistry

G protein-coupled receptors as targets for anti-diabetic therapeutics. (Nature Review Drug Discovery)

Late-stage diversification of biologically active molecules via chemoenzymatic  C-H functionalization. (ACS Catalysis)

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.(Nature Medicine)

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. (Science Translational Medicine)

Silence of the GUCY2C tumor suppressor. (Science Translational Medicine) 

Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. (Proceedings of the National Academy of Sciences)

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. (Nature)

Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies. (Neuron)

PPAR-δ is repressed in Huntington’s disease, is required for normal neuronal function and can be targeted therapeutically. (Nature Medicine)

A Systems-Level Analysis of the Peripheral Nerve Intrinsic Axonal Growth Program. (Neuron)

The stress regulator FKBP51 drives chronic pain by modulating spinal glucocorticoid signaling. (Science Transnational Medicine)

Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area. (Addiction Biology)

Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. (Science Signalling)

Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1. (Science Translational Medicine)

De Novo design at the edge of chaos. (Journal of Medicinal Chemistry)

Synthetic Chemistry

Dual C-F, C-H Functionalization via Photocatalysis: Access to Multifluorinated Biaryls. (Journal of the American Chemical Society)

Network Analysis Guided Synthesis of Weisaconitine D and Liljestrandinine. (Nature)

Practical Ni-Catalyzed Aryl-Alkyl Cross-Coupling of Secondary Redox-Active Esters. (Journal of the American Chemical Society)

Strain-release amination. (Science)

Aryl Nitriles from Alkynes Using tert-Butyl Nitrite: Metal-Free Approach to C≡C Bond Cleavage. (ACS Organic Letters)

An Improved System for the Aqueous Lipshutz-Negishi Cross-Coupling of Alkyl Halides with Aryl Electrophiles.(Angewandte Chemie)

Access to Difluoromethylated Arenes by Pd-Catalyzed Reaction of Arylboronic Acids with Bromodifluoroacetate. (ACS Organic Letters)

Direct Difluoromethylation of Aryl Halides via Base Metal Catalysis at Room Temperature. (Journal of the American Chemical Society)

Webinar: Tackling the #1 Drug Product Development Problem: Solubility May 5th

Webinar: Tackling the #1 Drug Product Development Problem: Solubility

Date: Thursday, May 5, 2016
Time: 10AM PST | 1PM EST | 6PM GMT
Duration: 1 hour
Complementary and open to life science professionals globally

Overview:

Despite significant advances and increased understanding of the importance of physicochemical properties in drugs and drug candidates, solubility is still the number 1 issue in drug product development.  Approximately 40% of approved drugs and 75% – 90% of developmental pipelines consist of drugs and drug candidates with poorly soluble characteristics, representing a substantial risk to successful drug development.  Remarkably, solubility is one of the properties that can be assessed and addressed early in drug discovery and development, well before candidates are selected or advanced into costly preclinical and clinical development.  In this complimentary live webinar, open to life science professionals globally, WuXi brings together scientific experts in pharmaceutical- and medicinal-chemistry sciences to address strategies in reducing program risk while increasing odds of success by “Tackling the #1 Drug Product Development Problem: Solubility”.

*A recording will be made available after the live webcast – Please register to receive more information.

Speakers:

Mui Cheung, Director, Medicinal Chemistry, GlaxoSmithKline
Manish Gupta, Head of Biopharmaceutics, Platform Technologies & Science, GlaxoSmithKline
Matt Burke, Head of Drug Delivery, Platform Technologies & Sciences, GlaxoSmithKline
Riccardo Panicucci, Vice President, Pharmaceutical Development Services, WuXi AppTec
Richard Soll, SVP, International Discovery Service Unit, WuXi AppTec (Moderator)

Speaker Bio:

Mui Cheung, Director, Medicinal Chemistry, GlaxoSmithKline

Mui Cheung graduated summa cum laude from Florida A&M University with a B.S. degree in Chemistry in 1993. She received her Ph.D. from Rice University in Organic Chemistry focusing on total synthesis of natural products and synthetic methodology development. Dr. Cheung joined GlaxoWellcome in 1997 as a medicinal chemist and has held increasing leadership responsibility over the years. Dr. Cheung is an accomplished research leader with over 18-year track record of leading large multi-disciplinary and transnational teams to deliver tools, leads and clinical candidates across a variety of therapeutic areas including oncology, urology, metabolic, cardiovascular, inflammation and dermatology. She has led or involved in teams that deliver 15 candidate selections of which six progressed to human clinical trials and one is a marketed product (Votrient®). Dr. Cheung is co-inventor of 59 NCE patents (29 issued US patents) including Votrient® and has co-authored over 130 publications, presentations and patent applications. Dr. Cheung is currently the Head of Chemistry in the Virtual Proof of Concept (VPoC) Discovery Performance Unit in GlaxoSmithKline and is responsible for managing and supporting a portfolio of early to late stage programs across multiple disease areas.

Manish Gupta, Head of Biopharmaceutics, Platform Technologies & Science, GlaxoSmithKline

Manish Gupta serves as the Head of Biopharmaceutics in the Platform Technologies & Science Department at GlaxoSmithKline. In this capacity, Dr. Gupta leads a global team to improve product design and control across oral, inhalation, and parenteral dosage forms based on the foundation of biopharmaceutics understanding. Prior to his current role, Dr. Gupta led a project team for a transformational asset to design a novel long acting parenteral product with the right balance between biopharmaceutics, stability and manufacturability. He has made significant scientific and leadership contributions towards successful commercialization of three oral products: Tykerb, Votrient, and Mekinist. Dr. Gupta has championed science and risk based product development approach for GSK’s first QbD file, Votrient, with extensive regulatory engagement. He received his Ph.D. from University of Connecticut studying amorphous systems.

Matt Burke, Head of Drug Delivery, Platform Technologies & Sciences, GlaxoSmithKline

Matt Burke serves as Head of Drug Delivery in the Platform Technologies & Science Department at GlaxoSmithKline. He leads a group guiding the drug delivery strategy at GSK, which includes internal development and application of technologies to the portfolio as well as external evaluation. Dr. Burke also serves as a project lead for assets in early clinical development and is a master subject matter expert on oral modified release and continuous manufacturing. Dr. Burke has worked at multiple sites in the US and UK within GSK, has approximately 30 articles, patents and symposium presentations. He has served as an adjunct professor at North Carolina State University Biomolecular and Chemical Engineering department and University of North Carolina at Chapel Hill School of Pharmacy and received his PhD in Oral Colonic Drug Delivery Systems.

Riccardo Panicucci, Vice President, Pharmaceutical Development Services, WuXi AppTec

Rick Panicucci joined WuXi AppTec in February 2015. As Vice President of Pharmaceutical Development Services, Dr. Panicucci provides scientific leadership for 160 scientists in Developability, Formulation Development, and GMP Manufacturing and is responsible for the execution of all Parenteral and Oral dosage form programs. He also maintains key client relationships and assesses new technologies through partnering or internal M&A capacity building. In addition to his position at WuXi, he currently serves as an Adjunct Professor at Massachusetts College of Pharmacy. Prior to WuXi, Dr. Panicucci was the Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015. His responsibilities included analytics, solid state chemistry and formulation development of all small molecule therapeutics in early development. He also helped develop novel drug delivery technologies for small molecules and large molecules including siRNA. Dr. Panicucci has also led groups in Formulation and Research and Development at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb. His education includes two post doctoral fellowships at University of California at Santa Barbara and the Ontario Cancer Institute. He received his Ph.D. in Physical Organic Chemistry from the University of Toronto.

Richard Soll, PhD, SVP, International Discovery Service Unit, WuXi AppTec

Dr. Richard Soll is Senior Vice President of the International Discovery Service Unit (IDSU) at WuXi AppTec. In this capacity, Dr. Soll leads the discovery synthetic- and medicinal-chemistry global collaborations at WuXi that aim to provide expertise and innovative solutions for small molecule drug R&D across biopharma and life science industries. In addition, Dr. Soll’s expanded responsibilities include oversight of the newly established WuXi offices in Cambridge, Massachusetts and Israel.  These offices bring WuXi’s comprehensive platform of integrated R&D services closer to innovative companies and entrepreneurs in the world’s two leading biotech hubs. Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals and was trained as a synthetic chemist at Dartmouth and Harvard. Dr. Soll’s drug discovery and development experiences has led to more than 100 patents and papers, and more than 10 drug candidates advancing to the clinic including drugs of breakthrough designation. Dr. Soll has been an SAB member to biotech companies and advisor to entrepreneurs.

SDpress April 2016

Innovation That Matters

Placing ‘Early’ Bets in Biotech – A Chat With Andy Schwab, Co-Founder & Managing Partner, 5AM Ventures

Next Generation Immuno-Oncology: Creating a New Pathway to ‘Eat’ Cancer – A Chat with Jonathan MacQuitty, CEO, Forty Seven

How ‘Cool’ Science Translates Into Successful Companies – A Chat with UNITY Biotechnology CEO, Nathaniel David 

Connecting the Global Autism Scientific Community – A Chat With Alan Packer, Senior Scientist, Simons Foundation Autism Research Initiative

Finding Solutions to Rare Diseases through Genomics: An Interview with Hannes Smárason, WuXi NextCODE

WuXi News

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia

WuXi Acquires Crelux

Juno Therapeutics and WuXi Start New Company to Develop Novel Cell-Based Cancer Immunotherapies in China

WuXi Lab Testing Division’s Analytical and Stability Testing Facilities Passed FDA Inspection

WuXi Opens Office in South Korea

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial

World’s Largest Autism Dataset Goes Online

WuXi NextCODE Becomes the First and Only CAP, CLIA, and California Accredited Sequencing Laboratory in China

Webinar: Tackling #1 Drug Development Problem: Solubility (May 5)

Huawei and WuXi Join Forces to Create China Precision Medicine Cloud Platform

WuXi’s STA Subsidiary Opens New Campus in Changzhou
In This Issue
Industry Beats

Top 10 San Diego Deals in Q1 (Source: Xconomy) 

Study Links Coffee Consumption to Decreased Risk of Colorectal Cancer (Source: USC)

Human Longevity Announces 10 Year Deal with AstraZeneca to Sequence and Analyze Patient Samples from AstraZeneca Clinical Trials (Source: Human Longevity)

Zavante Therapeutics Closes $45M Series A Financing in Support of U.S. Development for a First-in-class Injectable Antibiotic (Source: Zavante)

Human Longevity Completes $220M Series B Financing (Source: Human Longevity) 

EnsoData Raises $550K to Develop Software That Analyzes Sleep Data (Source: Xconomy)

RiverVest Venture Partners Opens San Diego Office That’s Been 10 Years in the Making (Source: RiverVest)

UCSD Scientist Named to Panel Advising Biden on Cancer ‘Moonshot’ (Source: UCSD)

Drug Approvals and Designations

Upcoming Events

April 28, 2016
LA BioMed, Torrance
 
April 29, 2016
Salk Institute, La Jolla
 
May 2, 2016
Biocom, San Diego
 
May 17, 2016
OCTANe, Orange Country
 
May 25, 2016
Biocom, San Diego
Follow us on TwitterView our profile on LinkedIn

BAYpress March 2016

WuXi Global Webinar “Pioneering Approaches to Dismantling Cancer”


 
Wednesday, April 6, 2016 (10AM-11AM PST)
Speakers include:
 
James Audia, CSO, Constellation Pharmaceuticals
Philip Gotwals, Executive Director, Exploratory Immuno-Oncology, Novartis Institutes of BioMedical Research
Jason Rhodes, Partner, Atlas Venture
Richard Soll, SVP, International Discovery Service Unit, WuXi AppTec (moderator)

Click here to register

Around Town

How ‘Cool’ Science Translates Into Successful Companies – A Chat with UNITY Biotechnology CEO, Nathaniel David

WuXi Spring Reception in San Francisco

Innovation That Matters

Finding Solutions to Rare Diseases through Genomics: An Interview with Hannes Smárason, WuXi NextCODE

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News

Huawei and WuXi Join Forces to Create China Precision Medicine Cloud Platform

WuXi Congratulates MSD on Receiving FDA Approval of ZEPATIER™

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia

Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement

World’s Largest Autism Dataset Goes Online

WuXi NextCODE Becomes the First and Only CAP, CLIA, and California Accredited Sequencing Laboratory in China

WuXi Releases New Mobile App for Compound Sourcing

WuXi Opens Office in South Korea

WuXi’s STA Subsidiary Opens New Campus in Changzhou

In This Issue
Industry Beats

Takeda and Frazier Healthcare Partners Launch Outpost Medicine to Develop New Therapeutics in Urology and Gynecology (Outpost Medicine)Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the U.S., Canada, and Japan (Source: Exelixis)

Startup Arterys Emerges with Diagnostic Technology (Source: WSJ)

23andMe Enables Genetic Research for ResearchKit Apps (Source: 23andMe)

Kite Pharma Enters Clinical Trial Collaboration with Genentech to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma (Source: Kite Pharma)

BioMarin Heads to FDA with Mixed Data For Rare Disease Drug (Source: Xconomy)

Dr. Reddy’s Buys U.S Rights to XenoPort’s Psoriasis Drug (Source: XenoPort)

Third Rock Ventures Launches Pliant Therapeutics with $45M Series A to Treat Fibrotic Diseases (Source: Pliant)

Stanford Spins Out Immunotherapy Work Funded by CIRM’s Millions (Source: Xconomy)

Google Ventures Leads $21M Series B for Epigenetic Sequencing Startup, as it Adds Ex-Illumina Exec as CEO (Source: FierceMedicalDevices)

Tizona Therapeutics Completes $43M Series B Financing (Source: Tizona)

Rani Therapeutics Completes Latest Round of Funding; Brings Total Investment to $70M (Source: Rani Therapeutics)

10x Genomics Completes $55M Series C Financing (Source: 10x Genomics)

Corvus Pharmaceuticals Announces Pricing of IPO (Source: Corvus)

HealthTell Completes A $26M Series B Financing (Source: BioSpace)

Sanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform (Source: Sanofi)

Caribou Bio’s New CRISPR Patent Isn’t About Gene Editing (Source: Xconomy)

FDA Drug Approvals & Designations

Merck Receives FDA Approval of ZEPATIER (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection (Source: Merck)

Upcoming Events

April 7, 2016
CLSA, Meno Park
April 14-15, 2016
Biotech Primer, South San Francisco
April 16-20, 2016
AACR, New Orleans
Visit us at booth #1756
 
June 6-9, 2016
BIO, San Francisco
Follow us on Twitter

MApress Newsletter March 2016

WuXi Global Webinar “Pioneering Approaches to Dismantling Cancer”


 
Wednesday, April 6, 2016 (10AM PST | 1PM EST | 6PM GMT)
Cancer continues to be a leading cause of morbidity and mortality worldwide with more than 8 million deaths and 14 million new cases per year.  Significant advances have been made to unravel cancer’s mysteries and complexities at the genetic-, molecular- and pathway-levels. They not only reveal new scientific insights into the biology of diseases, but also herald a new era with fresh perspectives for the prevention, diagnosis, and more effective, precision-driven therapies.  In this complimentary live webinar open to life science professionals globally, WuXi brings together scientific and executive leaders from pharma, biotech and the venture capital community to discuss “Pioneering Approaches to Dismantling Cancer.”
Our distinguished speakers include:
 
James Audia, CSO, Constellation Pharmaceuticals
Philip Gotwals, Executive Director, Exploratory Immuno-Oncology, Novartis Institutes of BioMedical Research
Jason Rhodes, Partner, Atlas Venture
Richard Soll, SVP, International Discovery Service Unit, WuXi AppTec (moderator)

Click here to register

Local Perspectives

Finding Solutions to Rare Diseases through Genomics: An Interview with Hannes Smárason, WuXi NextCODE

Innovation That Matters

How ‘Cool’ Science Translates Into Successful Companies – A Chat with UNITY Biotechnology CEO, Nathaniel David

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News

Huawei and WuXi Join Forces to Create China Precision Medicine Cloud Platform

World’s Largest Autism Dataset Goes Online

WuXi NextCODE Becomes the First and Only CAP, CLIA, and California Accredited Sequencing Laboratory in China

WuXi Healthcare Ventures Joins Financing Rounds for Twist Bioscience and Syros Pharmaceuticals

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia

WuXi Opens Office in South Korea

WuXi Spring Reception in San Francisco

Over 1,100 Executives Signed-up for 4th Annual WuXi Global Forum at J.P. Morgan Conference

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial

WuXi Releases New Mobile App for Compound Sourcing

WuXi’s STA Subsidiary Opens New Campus in Changzhou

WuXi Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic

WuXi Congratulates MSD on Receiving FDA Approval of ZEPATIER™

Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
In This Issue
Industry Beats

Sage Therapeutics to Present SAGE-547 Clinical Data and SRSE Health Economic Data in Five Abstracts at the American Academy of Neurology 2016 Annual Meeting (Source: Sage Therapeutics)WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018 (Source: WAVE Life Sciences)

First Four Biotech Startups of 2016 Begin MassCONNECT Program (Source: Boston Business Journal)

Allied-Bristol Life Sciences Launches iβeCa Therapeutics from NYU School of Medicine to Develop Novel Cancer Therapeutics Targeting the Wnt Pathway (Source: Allied Minds)

Bristol Meyers-Squibb to Aquire Padlock Therapeutics, Ltd. (Source: Padlock Therapeutics)

Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy (Source: Blueprint Medicines)

Bristol-Myers Squibb and LabCentral Team Up in Cambridge, Massachusetts to Support Promising Biotech Startup Companies (Source: Bristol-Myers Squibb)

Biogen Joins Pioneering Target Validation Collaboration (Source: Biogen)

AstraZeneca Enters Licensing Agreement with China Medical System Holdings for Hypertension Medicine (Source: AstraZeneca)

Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) (Source: Broad Institute)

Radius Health Announces Clinical Collaboration With a Leading Pharmaceutical Company to Evaluate RAD1901 Combination Regimens in Advanced Breast Cancer (Source: Radius Health)

AstraZeneca and BIND Therapeutics publish AZD2811 ACCURINS® data in Science Translational Medicine (Source: AstraZeneca)

Dana-Farber Cancer Institute’s Belfer Center announces Immuno-Oncology research collaboration with Array BioPharma (Source: Dana Farber Cancer Institute)

Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer® Antibody-Drug Conjugates and XMT-1522 (Source: Takeda Pharmaceuticals)

AstraZeneca and MedImmune enter consortium to deliver new treatments for chronic kidney disease (Source: AstraZeneca)

Quartet Medicine Announces Strategic Partnership with Merck (Source: Quartet Medicine)

Rodin Announces New Equity Financing and R&D Collaboration with Biogen (Source: Rodin Therapeutics)

Shire to Combine with Baxalta, Creating the Global Leader in Rare Diseases (Source: Baxalta)

Tesaro Announces Definitive Agreement for $155 Million Private Placement (Source: Tesaro)

Pronutria Biosciences Announces $42.5 Million Equity Investment from Nestle Health Science (Source: Pronutria Biosciences)

Synlogic Secures $40 Million in Series B Financing (Source: Synlogic)

Yumanity Therapeutics Closes $45 Million Series A Financing (Source: Yumanity Therapeutics)

Aquinnah Pharmaceuticals Receives $5 Million Investment from Takeda Pharmaceuticals to Advance New Therapies in ALS (Source: Business Journals)

Spero Therapeutics Announces $30 Million Series B Preferred Financing (Source: Spero Therapeutics)

Pear Therapeutics Closes $20 Million Financing (Source: Pear Therapeutics)

Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/CAS9 (Source: Intellia Therapeutics)

Codiak BioSciences Closes $61 Million Series B Financing (Source: PR Newswire)

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares (Source: Editas Medicine)

Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics (Source: Tarveda Therapeutics)

Theracos Raises $25M to Take on Big Pharma in Diabetes (Source: FierceBiotech)

5AM Ventures launching stealth (RNA?) startup Homology Medicines with $23M (Source: MedCity News)

Scholar Rock Announces $36 Million Series B Financing (Source: Scholar Rock)

Navitor Pharmaceuticals Announces $33 Million Series B Financing (Source: Navitor Pharmaceuticals)

Partners HealthCare announces new round of Innovation Grants (Source: Partners Healthcare)

FDA Drug Approvals & Designations

Merck Receives FDA Approval of ZEPATIER (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection (Source: Merck)

Upcoming Events

March 31 – April 1, 2016
Boston Marriott Cambridge Hotel, Cambridge
March 31 – April 1, 2016
Royal Sonesta, Cambridge, MA
April 5, 2016
MassBio, Technology Square, Cambridge
April 12, 2016
Merck Research Laboratories, Boston
April 20, 2016
Westin Copley Place, Boston
 
April 25-27, 2016
Westin Copley Place, Boston
 
April 28, 2016
Royal Sonesta, Cambridge
Follow us on TwitterView our profile on LinkedIn